Drug Profile


Alternative Names: Artrolasi; Copper zinc SOD; Cu/Zn-superoxide dismutase; Interceptor; Ontosein; Orgo-M; Ormetein; Peroxinorm; Serosod; Superoxide dismutase - Oxis

Latest Information Update: 16 May 2011

Price : $50

At a glance

  • Originator OXIS International
  • Developer Tedec Meiji
  • Class Anti-inflammatories; Antirheumatics; Metalloproteins; Radioprotectives
  • Mechanism of Action Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cystitis; Radioprotection; Rheumatic disorders
  • Discontinued Reperfusion injury

Most Recent Events

  • 31 Mar 2011 Orgotein is available for licensing as of 31 Mar 2011.
  • 22 Mar 2004 OXIS International has been acquired by Axonyx
  • 14 Dec 1999 Oxis International is no longer pursuing an active research programme in bovine superoxide dismutase products
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top